Abstract

PurposeThis prospective study aimed to evaluate the changes in functional outcomes and quality of life after the injection of botulinum toxin (BTX) into the masticatory muscles for the management of myogenic temporomandibular disorders (TMDs). Materials and MethodsThis study was conducted with 45 individuals who presented with clinically myogenic TMDs according to the Diagnostic Criteria for Temporomandibular Disorders. All patients received BTX injections in the temporalis and masseter muscles. The Oral Health Impact Profile–Temporomandibular Dysfunction (OHIP–TMD) questionnaire was used to evaluate the effects of treatment on quality of life. The OHIP–TMD, visual analogue scale (VAS), and maximum mouth opening (MMO) scores before and 3 months after BTX injection were evaluated. ResultsThe preoperative and postoperative assessments revealed a statistically significant reduction (p ≤ 0.001) in the average overall OHIP–TMD scores. A significant increase in the MMO scores and a significant decrease in the VAS scores were observed (p < 0.001). ConclusionsThe injection of BTX into the masticatory muscles is beneficial for improving the clinical and quality of life parameters in the management of myogenic TMD.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call